Want to see SANA full AI Analyst Report?
SANA Stock Chart & Stats
$4.10
$3.38(204.85%)
At close: 4:00 PM EST
$4.10
$3.38(204.85%)
Day’s Range― - ―
52-Week Range$2.61 - $6.55
Previous CloseN/A
Volume118.31M
Average Volume (3M)3.19M
Market Cap
$928.02M
Enterprise Value$940.93
Total Cash (Recent Filing)$160.49M
Total Debt (Recent Filing)$73.74M
Price to Earnings (P/E)―
Beta1.63
Next Earnings
Nov 05, 2026EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.76
Shares Outstanding299,360,630
10 Day Avg. Volume4,644,031
30 Day Avg. Volume3,185,919
Financial Highlights & Ratios
PEG Ratio0.25
Price to Book (P/B)6.41
Price to Sales (P/S)0.00
P/FCF Ratio-7.12
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$8.00Price Target Upside95.12% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.67
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Durable Hypoimmune Cell ValidationThe 14-month first-in-human UP421 data provide clinical validation for Sana’s hypoimmune cell approach, including survival, function, and immune evasion without immunosuppression. This supports the platform’s potential durability and may reduce treatment complexity if replicated in broader studies.
Progress Toward T1D Clinical DevelopmentAdvancing SC451 toward IND readiness demonstrates movement from scientific validation toward a broader stem cell-derived therapy for type 1 diabetes. Completion of toxicology, manufacturing scale-up, and planned clinical testing could create a more tangible development path and expand the addressable patient population.
Off-the-shelf Oncology PlatformThe in vivo CAR T strategy is designed to deliver cell-specific therapy without conditioning chemotherapy while preserving off-the-shelf availability. If supported by the cited non-human-primate data and future human studies, this could differentiate Sana’s approach and improve treatment accessibility.
Bears Say
No Demonstrated Revenue EngineSana has not demonstrated a recurring product-revenue base, while TTM net loss remains about $212 million. This development-stage profile means fundamental value still depends on advancing programs to commercialization or partnerships, leaving results highly exposed to clinical and regulatory execution.
Persistent Cash-flow DeficitNegative operating and free cash flow show that Sana’s research platform currently consumes substantial cash rather than funding itself. Although the burn rate improved from 2023–2024, continued deficits may require external financing before revenue ramps, potentially limiting strategic flexibility.
Material Equity ErosionThe steep decline in equity indicates that accumulated losses and cash consumption have materially reduced the company’s financial base. Even with moderate debt-to-equity near 0.48, this erosion can weaken resilience and increase dependence on future financing to sustain long-duration development programs.
Sana Biotechnology News
SANA FAQ
What was Sana Biotechnology’s price range in the past 12 months?
Sana Biotechnology lowest stock price was $2.61 and its highest was $6.55 in the past 12 months.
What is Sana Biotechnology’s market cap?
Sana Biotechnology’s market cap is $928.02M.
When is Sana Biotechnology’s upcoming earnings report date?
Sana Biotechnology’s upcoming earnings report date is Nov 05, 2026 which is in 44 days.
How were Sana Biotechnology’s earnings last quarter?
Sana Biotechnology released its earnings results on Aug 10, 2026. The company reported -$0.22 earnings per share for the quarter, missing the consensus estimate of -$0.147 by -$0.073.
Is Sana Biotechnology overvalued?
According to Wall Street analysts Sana Biotechnology’s price is currently Undervalued.
Does Sana Biotechnology pay dividends?
Sana Biotechnology does not currently pay dividends.
What is Sana Biotechnology’s EPS estimate?
Sana Biotechnology’s EPS estimate is -0.15.
How many shares outstanding does Sana Biotechnology have?
Sana Biotechnology has 299,360,630 shares outstanding.
What happened to Sana Biotechnology’s price movement after its last earnings report?
Sana Biotechnology reported an EPS of -$0.22 in its last earnings report, missing expectations of -$0.147. Following the earnings report the stock price went up 4.986%.
Which hedge fund is a major shareholder of Sana Biotechnology?
Currently, no hedge funds are holding shares in SANA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sana Biotechnology Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.00 (95.12% Upside)
$8.00 (95.12% Upside)
Blogger Sentiment
Neutral
SANA Sentiment 50%
Sector Average 63%
Sector Average 63%
Hedge Fund Trend
Increased
By 18.7M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 1.3%
Last 30 Days ▲ 0.7%
Last 30 Days ▲ 0.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-5.77%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
19.32%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Sana Biotechnology
Sana Biotechnology, Inc. is a biotechnology firm focused on creating treatments using engineered cells. The company develops advanced ex vivo and in vivo cell engineering platforms to address a range of conditions with significant unmet medical needs, including various cancers, diabetes, central nervous system disorders, cardiovascular diseases, and genetic illnesses. Its portfolio of drug candidates includes SG295 and SG242, which are designed to target CD19+ cancer cells involved in non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia. For multiple myeloma, Sana is progressing SG221, SG239, and SC255. Other pipeline assets include SG328 for ornithine transcarbamylase deficiency, and SG418 for sickle cell disease and beta-thalassemia. Additionally, the company is advancing SC291, a CD19 allogeneic T cell therapy, SC451 for type I diabetes mellitus, and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease. Founded in 2018 as FD Therapeutics, Inc., the company adopted its current name, Sana Biotechnology, Inc., in September 2018 and is based in Seattle, Washington.
SANA Stock 12 Month Forecast
Average Price Target
$8.00
▲(95.12% Upside)
Technical Analysis
Geron
―
Editas Medicine
―
Crispr Therapeutics AG
―
Taysha Gene Therapies
―
Prime Medicine, Inc.
―
Ownership Overview
13.64% Insiders
10.91% Mutual Funds
18.85% Other Institutional Investors
46.55% Public Companies and
Individual Investors